# Adversarial Plan-Review: Stage 7 Answerability Summary (executive-readable)

**Feature**: `053-stage-7-answerability-summary-executive`
**Date**: 2026-07-01
**Reviewer stance**: single default-adverse skeptic, READ-ONLY over spec.md / plan.md /
tasks.md / analysis.md. I report fixes; I edit nothing, approve nothing, and never retry.

**Prerequisite gate**: spec.md, plan.md, tasks.md, and analysis.md all present and
committed on this branch -> NOT auto-BLOCKED.

## Axis 1 -- hidden-principle-violation

Looking for any place the artifact self-grants a human approval, moves a readiness stage to
`pass`, or resolves a Principle-V judgment call.

- FR-006 forbids granting approval or moving a stage; FR-007 forces the `publish-ready.md`
  reference to be non-gating (absent from Required artifacts / Required checks / Blocking
  reasons); T008 verifies the no-gating-leak. Consistent with `publish-ready.md`, whose
  publish approval is a named human sign-off in `approvals[]`.
- The two Principle-V calls (FR-014 PII publish-safety, FR-015 severity/priority ordering)
  are marked [NEEDS CLARIFICATION], recorded in `## Clarifications` as deferred-to-human, and
  T011 records-not-resolves them. No artifact answers them.
- **Verdict**: no violation. The one residual risk is presentational: an executive
  "answerable today" list could be *read* as an implicit readiness/publish endorsement. The
  spec mitigates this (US1 test + FR-006 "presentation over the human seam"), but the exact
  PII-safety posture is precisely FR-014, correctly left open. Acceptable.

## Axis 2 -- assumes-deferred-capability

- F016 (Power BI execution adapter) is treated as absent in spec (FR-009), plan (Deferred
  section, rule #6 gate row), and tasks (T006 paper-answerable note). "Answerable today" is
  explicitly paper-answerable, never live-validated.
- F031-F033 named only to exclude. No task depends on any unbuilt runtime.
- **Verdict**: no deferred-capability assumption. Clean.

## Axis 3 -- c086-leak

- The named risk (grounding): the F8 scorecard's worked example is `raw.sales` with VAT /
  returns ambiguities that read as generic retail but can shade toward C086 pharmacy framing.
- Mitigation is explicit and testable: FR-008 requires placeholders + generic KPI/domain
  names only; T010 is a dedicated C086-leak scan; T009 cites `docs/worked-examples/
  c086-pharmacy.md` by reference. The template composes the F8 *status vocabulary*, not the
  F8 worked-example rows.
- **Residual note (not a finding)**: the builder must resist copying the F8 worked-example
  `raw.sales` table verbatim into the template as an "illustration"; that table, while
  labelled illustrative, carries concrete retail field names. The plan's design note and
  T010 scan cover this, but the builder should keep any inline illustration to generic
  `<placeholder>` tokens and reach `raw.sales`/pharmacy specifics only by reference.
- **Verdict**: no leak in the plan; one builder-discipline note carried forward.

## Axis 4 -- fabricated-confidence

- Rule #9 / F8 no-score discipline is asserted in spec (FR-005, SC-002), plan (Constitution
  Check row), and tasks (T012 explicit "sweep for any numeric coverage/confidence figure ->
  must be zero"). Coverage is status + named blocker only.
- The all-blocked edge case is handled without a fabricated positive (T003 "none today"
  note).
- **Verdict**: no fabricated confidence. Clean.

## Axis 5 -- over-scope

- Scope is two files: one new template, one one-line non-gating doc edit. No runtime code,
  no new `retail check` rule (rule count stays 38; T012, SC-006).
- The adjacent-but-distinct idea in the backlog (a fail-closed LINTER over *filled* scorecard
  instances -- status-enum / blocker-presence / no-% checks, which would add an
  EXPECTED_RULE_ID) is explicitly OUT of scope in the plan's "Deferred / not-in-scope"
  section. This feature is presentation-only; it does not drift into that validator.
- **Verdict**: no over-scope. YAGNI respected -- the seam (non-gating reference) is added,
  not the implementation.

## Findings carried from analyze

- LOW-1 (analysis.md): FR-011 "invent no rollup/segment/grouping" has no dedicated task ID;
  it is covered transitively by compose-only tasks T003-T005 + the T010 scan. Non-blocking;
  suggested that T010/T012 add an explicit "no invented grouping" confirmation. I concur:
  LOW, does not block.

## Verdict

**Verdict**: PASS-WITH-NOTES

- hidden-principle-violation: PASS
- assumes-deferred-capability: PASS
- c086-leak: PASS (one builder-discipline note)
- fabricated-confidence: PASS
- over-scope: PASS

**plan_review_verdict: PASS-WITH-NOTES**

Notes for the builder (all non-blocking):
1. Keep any inline illustration to generic `<placeholder>` tokens; reach `raw.sales` /
   pharmacy specifics ONLY by reference to the worked example (Axis 3).
2. Add an explicit "no invented grouping / rollup / segment beyond F7 domain files"
   confirmation to T010 or T012 to close LOW-1's implicit-coverage nit.
3. FR-014 (PII posture) and FR-015 (severity ordering) remain human rulings -- the builder
   records them as open items in the template and does NOT resolve them.

No CRITICAL or HIGH findings. The spec is ratifiable; ratification is a human action this
review does not perform.
